Daily Archives: July 1, 2019

Philips Foundation publishes 2018 Annual Report

July 1, 2019

Amsterdam, the Netherlands The Philips Foundation, established by Royal Philips (NYSE: PHG; AEX: PHIA) as the central platform for Philips’ CSR activities, today announced publication of its 2018 Annual Report. The report highlights the Foundation’s solid progress in delivering on its commitment to reduce health inequality through meaningful innovation. This includes support for local NGO projects, collaboration with international organizations, and support for social entrepreneurs seeking to implement innovative healthcare solutions. Via the Foundation, Philips also focuses its workforce’s volunteering activities on a single global healthcare issue to achieve greater impact.

Building on its commitment to help solve some of the world’s most difficult healthcare challenges through innovation and collaboration, the Philips Foundation deliberately steered away from traditional donations in 2018. Instead, it teamed up with complementary partners, such as national Red Cross societies, UNICEF, ICRC, Save the Children and Amref, and with specific social entrepreneurs, resulting in the launch of 40 exciting new projects that explore new models of access to care to strengthen healthcare systems, improve outcomes, and reduce the cost of care.

“Standing shoulder to shoulder with our partners and of course Philips’ workforce, the Philips Foundation focuses on providing high-quality healthcare to communities lacking affordable and sustainable facilities,” said Margot Cooijmans, Director Philips Foundation. “In developing and deploying innovative solutions the Philips Foundation leverages the heads and hands, skills and technologies of Philips and its employees worldwide, to serve the health and well-being of disadvantaged people. To date, over 150 projects are running, improving the lives of more than 10 million people.”

Social entrepreneurship – accelerating access to care in collaboration with Ashoka
The Philips Foundation and Ashoka, the largest global network of leading social entrepreneurs, have completed the first year of a three-year collaboration to increase access to healthcare around the world. By connecting leaders in Philips with innovative social entrepreneurs, the aim is to optimally leverage business capabilities and achieve greater impact. In 2018, five new social entrepreneurs were selected, all committed to accelerating access to healthcare in underserved communities of Africa, Asia, and Latin America. Combining the business strengths of Philips and the system-changing capabilities of social entrepreneurs will allow the co-creation of solutions and the establishment of win-win partnerships to reduce health inequality and build sustainable access to primary healthcare.

Employee volunteering – making an impact on a key global access-to-healthcare issue
Through its employee team-volunteering program, the Philips Foundation provides a platform for more than 75,000 Philips employees to volunteer and make an impact on a key global access-to-healthcare issue. The focused goal for 2018 and 2019 is to reduce childhood pneumonia – a respiratory disease that can be relatively easily prevented, diagnosed and treated. Working closely with its strong network of NGOs, including Amref, the UN Foundation, Save the Children and the Red Cross, the Philips Foundation has identified impactful challenges, such as brain challenges, hands-on challenges and fundraising opportunities, that support the fight against childhood pneumonia. In 2018, the Philips Foundation facilitated deployment of up to 4,800 hours of volunteer work.

To read the Philips Foundation’s full Annual Report, please click here.

For further information, please contact:

Koen Joosse
Philips Foundation
Tel.: +31 6 1339 2233
E-mail: koen.joosse@philips.com

About the Philips Foundation
The Philips Foundation is a registered charity that was established in July 2014 as the central platform for Philips’ CSR activities. Reflecting our commitment to United Nations Sustainable Development Goals 3 (Ensure healthy lives and promote well-being for all at all ages) and 17 (Revitalize the global partnership for sustainable development), the mission of the Foundation is to reduce healthcare inequality by providing access to quality healthcare for disadvantaged communities. We do this by deploying Philips’ expertise, innovative products and solutions, by collaborating with key partners around the world and by providing financial support for collaborative activities. More information on the Philips Foundation can be found at https://www.philips-foundation.com.

Attachment

Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval

NANOBIOTIX ANNOUNCES NEW ORGANIZATIONAL STRUCTURE AS THE COMPANY ENTERS ITS NEXT STAGE AFTER FIRST EUROPEAN MARKET APPROVAL

  • Recently appointed Chief Medical Officer (CMO) Edwina Baskin-Bey, M.D., will join the Executive Board
  • Anne-Juliette Hermant, M.A., will be appointed Chief People Officer (CPO) and will join the Executive Board
  • Former CMO Elsa Borghi, M.D., will lead innovation and drug discovery for the company while leaving the Executive Board to focus on her new responsibilities
  • Chief Business Officer (CBO) Bernd Muehlenweg, Ph.D., will step down from the Executive Board and  exit the company
  • Patrick Tricoli, Pharm.D. M.B.A., will remain CEO of Nanobiotix Corp, the company’s U.S. affiliate, and also take on a new role as the Global Head of Business Development
  • Brandon Owens will be appointed Vice President (VP) of Strategic Marketing and Corporate Communications        

“As we enter our next stage as a company after receiving our first European market approval for Hensify® (NBTXR3) in Soft Tissue Sarcoma, we feel it is necessary to ensure we are optimally structured for continued success. As such, we are delighted to welcome our newcomers and congratulate those stepping into new roles. I also want to personally thank Dr. Bernd Muehlenweg, without whom we never would have achieved the business successes we have realized to this point. We are in a new era at Nanobiotix and I am confident these changes will serve to accelerate our growth.” – Laurent Levy, CEO of Nanobiotix            

Paris, France and Cambridge, Massachusetts, USA, July 1, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced organizational  changes to align with strategic priorities post European market approval for Hensify® (NBTXR3). The changes aim to reinforce necessary competencies as strategic priorities evolve, and to help accelerate the company’s longstanding mission to significantly improve outcomes for patients.

New C-level Appointments and Executive Board Members
Recently appointed CMO Dr. Edwina Baskin-Bey will join the Executive Board. Ms. Anne-Juliette Hermant will be appointed CPO and will join the Executive Board as well.

C-level and Executive Board Departures
As mentioned in a previous press release, former CMO Dr. Elsa Borghi will leave the Executive Board to take on a new function leading innovation and drug discovery. CBO Dr. Bernd Muehlenweg will step down from the Executive Board and exit the company.

New Management Appointments and Responsibilities
Dr. Patrick Tricoli will remain CEO of Nanobiotix Corp, the company’s U.S. affiliate, while also taking on a new role as Global Head of Business Development. Mr. Brandon Owens will join Nanobiotix as its newly appointed VP of Strategic Marketing and Corporate Communications.

Newcomer Biographical Details

Ms. Anne-Juliette Hermant
Anne-Juliette Hermant brings over 14 years of experience in HR, talent management and development, acquired across various entities at AXA. Ms. Hermant worked at AXA Partners for 3 years as Global Head of Talent, Development, Culture and Corporate Responsibility.

Before AXA Partners, Anne-Juliette served as Chief Learning Officer of the AXA Group and was the Founder and Head of the AXA Research Fund, a €100 million fund created by the AXA Group to support frontier science in all fields related to an understanding of the risks faced by human society.

Anne-Juliette was born in Strasbourg, France and grew up between the French overseas territories of Guyane, Martinique and Guadeloupe. She relocated to Lyon and then to Paris to pursue her studies and has remained in the city throughout her career.

Anne-Juliette graduated from the Ecole Normale Supérieure and studied Politics at Sciences Po Paris. She holds an Agregation and an M.A. in French literature.

Mr. Brandon Owens
Brandon Owens is a career communications professional that most recently functioned as a Vice President on the Citigroup account at Publicis New York. Mr. Owens was responsible for Citi’s global reputation management communications and focused on integrated campaigns meant to influence policy decisions relevant to banking in over 100 different countries.

Prior to Publicis, Brandon worked at agencies in both New York and Chicago, leading accounts including Procter and Gamble, Verizon Wireless, and Diageo.

Originally, Brandon comes from the Washington, D.C. area of the United States. After starting his career in sales for a small software firm in Baltimore, Maryland, he moved to Chicago to begin his career in advertising. From there he moved to New York City where he presently resides.

Brandon received his B.S. in Business from the Robert H. Smith School of Business at the University of Maryland.

About NANOBIOTIX: www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

Contacts

Nanobiotix

Communications Department
+33 (0)1 40 26 07 55
+1 (617) 852-4835
contact@nanobiotix.com

 

Investor Relations Department
+33 (0)1 79 97 29 99
+1 (646) 241-4400
investors@nanobiotix.com

Media relations

France – Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
marina@springbok.fr

United States – RooneyPartners
Marion Janic
+1 (212) 223-4017
mjanic@rooneyco.com

 

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorité des Marchés Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

Attachment

Cigarette industry eyes universities to promote its products

Jakarta (ANTARA) – The Human Rights Working Group (HRWG) drew attention to the worrisome trend of the cigarette industry targeting universities for promotional and sponsor activities of its products.

“The tobacco and cigarette industry has up its sleeve several strategies to continue its business, including through getting involved in universities,” Deputy Director of HRWG Daniel Awigra noted in Jakarta on Monday.

The universities’ Student Executive Board (BEM) should have a firm stance to solve the promotional and sponsor issue of the cigarette industry.

An aspect to bear in mind about this issue is that the objective behind promoting cigarettes runs counter to Indonesia’s demographic bonus in 2020-2045.

“How will productivity be in line with the working-age population if now many of them smoke?” Awigra cautioned.

Moreover, smoking has dire impacts on the health and economy since it is causal to several diseases.

Source: Antara News

Cigarette industry eyes universities to promote its products

Jakarta (ANTARA) – The Human Rights Working Group (HRWG) drew attention to the worrisome trend of the cigarette industry targeting universities for promotional and sponsor activities of its products.

“The tobacco and cigarette industry has up its sleeve several strategies to continue its business, including through getting involved in universities,” Deputy Director of HRWG Daniel Awigra noted in Jakarta on Monday.

The universities’ Student Executive Board (BEM) should have a firm stance to solve the promotional and sponsor issue of the cigarette industry.

An aspect to bear in mind about this issue is that the objective behind promoting cigarettes runs counter to Indonesia’s demographic bonus in 2020-2045.

“How will productivity be in line with the working-age population if now many of them smoke?” Awigra cautioned.

Moreover, smoking has dire impacts on the health and economy since it is causal to several diseases.

Source: Antara News